The University of Southampton
University of Southampton Institutional Repository

Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model

Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model
Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model
ObjectiveTo investigate the relative impact of generic entry and National Institute for Health and Care Excellence clinical guidelines on prescribing using statins as an exemplar.DesignRetrospective analysis of statin prescribing in primary care and cost simulation model.SettingRoyal College of General Practitioners Research and Surveillance Centre (RCGP R&SC) database and Prescription Cost Analysis (PCA) database.ParticipantsNew patients prescribed statins for the first time between July 2003 and September 2018.Main outcome measuresShares of new patients prescribed one of the five statins available in the British National Formulary, and cost of prescribing statins to new and existing patients in primary care in England.ResultsGeneral trends of statin’ prescriptions were largely driven by a decrease in acquisition costs triggered by patent expiration, preceding NICE guidelines which themselves did not seem to affect prescription trends. Significant heterogeneity is observed in the prescription of the most cost-effective statin acrossGPs. A cost simulation shows that, between 2004 and 2018, the NHS could have saved £2.8bn (around 40% of the £6.3bn spent on statins during this time) if all GP practices had prescribed only the most cost-effective treatment.ConclusionsThere is potential for large savings for the NHS if new and, whenever possible, ongoing patients are promptly switched to the first medicine that becomes available as generic within a therapeutic class as long as it has similar efficacy to still-patented medicines.
figshare
De Zarate, Matias Ortiz
3ecb2c94-8c11-4c3f-a588-2fef2ac18ee3
Ornaghi, Carmine
33275e47-4642-4023-a195-39c91d0146b0
Roderick, Paul
dbb3cd11-4c51-4844-982b-0eb30ad5085a
Mentzakis, Emmanouil
c0922185-18c7-49c2-a659-8ee6d89b5d74
Rutter, Paul
162ac51a-8770-4b6f-a95f-d8dd5effe706
Fraser, Simon DS
135884b6-8737-4e8a-a98c-5d803ac7a2dc
De Zarate, Matias Ortiz
3ecb2c94-8c11-4c3f-a588-2fef2ac18ee3
Ornaghi, Carmine
33275e47-4642-4023-a195-39c91d0146b0
Roderick, Paul
dbb3cd11-4c51-4844-982b-0eb30ad5085a
Mentzakis, Emmanouil
c0922185-18c7-49c2-a659-8ee6d89b5d74
Rutter, Paul
162ac51a-8770-4b6f-a95f-d8dd5effe706
Fraser, Simon DS
135884b6-8737-4e8a-a98c-5d803ac7a2dc

(2022) Price versus clinical guidelines in primary care statin prescribing: a retrospective cohort study and cost simulation model. figshare doi:10.25384/sage.c.5900083 [Dataset]

Record type: Dataset

Abstract

ObjectiveTo investigate the relative impact of generic entry and National Institute for Health and Care Excellence clinical guidelines on prescribing using statins as an exemplar.DesignRetrospective analysis of statin prescribing in primary care and cost simulation model.SettingRoyal College of General Practitioners Research and Surveillance Centre (RCGP R&SC) database and Prescription Cost Analysis (PCA) database.ParticipantsNew patients prescribed statins for the first time between July 2003 and September 2018.Main outcome measuresShares of new patients prescribed one of the five statins available in the British National Formulary, and cost of prescribing statins to new and existing patients in primary care in England.ResultsGeneral trends of statin’ prescriptions were largely driven by a decrease in acquisition costs triggered by patent expiration, preceding NICE guidelines which themselves did not seem to affect prescription trends. Significant heterogeneity is observed in the prescription of the most cost-effective statin acrossGPs. A cost simulation shows that, between 2004 and 2018, the NHS could have saved £2.8bn (around 40% of the £6.3bn spent on statins during this time) if all GP practices had prescribed only the most cost-effective treatment.ConclusionsThere is potential for large savings for the NHS if new and, whenever possible, ongoing patients are promptly switched to the first medicine that becomes available as generic within a therapeutic class as long as it has similar efficacy to still-patented medicines.

This record has no associated files available for download.

More information

Published date: 1 January 2022

Identifiers

Local EPrints ID: 478913
URI: http://eprints.soton.ac.uk/id/eprint/478913
PURE UUID: 1184dfb8-a09f-401e-b5dd-e1d8e4ef74da
ORCID for Carmine Ornaghi: ORCID iD orcid.org/0000-0003-2704-2537
ORCID for Paul Roderick: ORCID iD orcid.org/0000-0001-9475-6850
ORCID for Emmanouil Mentzakis: ORCID iD orcid.org/0000-0003-1761-209X
ORCID for Simon DS Fraser: ORCID iD orcid.org/0000-0002-4172-4406

Catalogue record

Date deposited: 13 Jul 2023 16:47
Last modified: 23 Feb 2024 02:47

Export record

Altmetrics

Contributors

Contributor: Matias Ortiz De Zarate
Contributor: Carmine Ornaghi ORCID iD
Contributor: Paul Roderick ORCID iD
Contributor: Emmanouil Mentzakis ORCID iD
Contributor: Paul Rutter
Contributor: Simon DS Fraser ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×